ES2184865T3 - Peptido para inhibir el aumento del nivel de trigliceridos en sangre einhibidor para el aumento del nivel de trigliceridos en sangre que comprende el peptido como ingrediente activo. - Google Patents

Peptido para inhibir el aumento del nivel de trigliceridos en sangre einhibidor para el aumento del nivel de trigliceridos en sangre que comprende el peptido como ingrediente activo.

Info

Publication number
ES2184865T3
ES2184865T3 ES96916354T ES96916354T ES2184865T3 ES 2184865 T3 ES2184865 T3 ES 2184865T3 ES 96916354 T ES96916354 T ES 96916354T ES 96916354 T ES96916354 T ES 96916354T ES 2184865 T3 ES2184865 T3 ES 2184865T3
Authority
ES
Spain
Prior art keywords
peptide
blood
triglicerids
level
increase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96916354T
Other languages
English (en)
Inventor
Kyoichi Kagawa
Hisako Matsutaka
Chizuko Fukuhama
Hiroaki Fujino
Masahiro Numata
Kazuhisa Honda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hankyo Kyoei Bussan Co Ltd
Original Assignee
Hankyo Kyoei Bussan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hankyo Kyoei Bussan Co Ltd filed Critical Hankyo Kyoei Bussan Co Ltd
Application granted granted Critical
Publication of ES2184865T3 publication Critical patent/ES2184865T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE UN PEPTIDO QUE PRESENTA UNA SECUENCIA DE AMINOACIDOS DE VAL - VAL - TYR - PRO, ASI COMO DE UN AGENTE PARA INHIBIR LOS AUMENTOS DE LOS NIVELES DE TRIGLICERIDOS EN SANGRE, DE UN ALIMENTO PARA UN USO EN SALUD ESPECIFICADO (LOS LLAMADOS ALIMENTOS FISIOLOGICAMENTE FUNCIONALES) Y DE UN PIENSO QUE INCLUYE EL ANTERIOR PEPTIDO COMO COMPONENTE ACTIVO. SEGUN LA PRESENTE INVENCION, SE OBTIENE UN PEPTIDO QUE INHIBE LOS AUMENTOS DE LOS NIVELES DE TRIGLICERIDOS EN SANGRE, ASI COMO UN AGENTE PARA INHIBIR LOS AUMENTOS DE LOS NIVELES DE TRIGLICERIDOS EN SANGRE, UN ALIMENTO FISIOLOGICAMENTE FUNCIONAL Y UN PIENSO, INCLUYENDO TODOS ELLOS EL PEPTIDO COMO COMPONENTE ACTIVO. CON ESTOS PRODUCTOS DE LA INVENCION, RESULTA POSIBLE PREVENIR O TRATAR LA OBESIDAD Y LA HIPERLIPEMIA EN HUMANOS Y ANIMALES, ASI COMO ENFERMEDADES DEL SISTEMA CIRCULATORIO, TAL COMO LA HIPERTENSION Y LA ARTERIOESCLEROSIS ASOCIADA A ELLA. ADEMAS, LOS MATERIALES DE LA INVENCION POSIBILITAN LA MEJORA DE LA CALIDAD DELA CARNE DE GANADO Y DE PECES DE VIVERO.
ES96916354T 1996-03-22 1996-06-10 Peptido para inhibir el aumento del nivel de trigliceridos en sangre einhibidor para el aumento del nivel de trigliceridos en sangre que comprende el peptido como ingrediente activo. Expired - Lifetime ES2184865T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8066916A JP2805194B2 (ja) 1996-03-22 1996-03-22 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤

Publications (1)

Publication Number Publication Date
ES2184865T3 true ES2184865T3 (es) 2003-04-16

Family

ID=13329785

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96916354T Expired - Lifetime ES2184865T3 (es) 1996-03-22 1996-06-10 Peptido para inhibir el aumento del nivel de trigliceridos en sangre einhibidor para el aumento del nivel de trigliceridos en sangre que comprende el peptido como ingrediente activo.

Country Status (11)

Country Link
US (1) US5958885A (es)
EP (1) EP0838473B1 (es)
JP (1) JP2805194B2 (es)
KR (1) KR100264344B1 (es)
AT (1) ATE225803T1 (es)
AU (1) AU690853B2 (es)
CA (1) CA2221767C (es)
DK (1) DK0838473T3 (es)
ES (1) ES2184865T3 (es)
NO (1) NO325836B1 (es)
WO (1) WO1997035875A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000095794A (ja) * 1998-09-22 2000-04-04 Itoham Foods Inc エンケファリン分解酵素の阻害剤
JP2000264845A (ja) * 1999-02-04 2000-09-26 Nippon Synthetic Chem Ind Co Ltd:The コレステロール降下剤及びその用途
WO2001068674A2 (en) * 2000-03-13 2001-09-20 Monsanto Technology Llc Preparation of recombinant proteins containing repeating units
DE10105041A1 (de) * 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
US20070254889A1 (en) * 2001-04-23 2007-11-01 Lee-Way Jin Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease
AU2003225277A1 (en) * 2002-05-02 2003-11-17 Robert Harris Lipid removal from the body
GB0211849D0 (en) * 2002-05-23 2002-07-03 Mok Kenneth H Improvments to retro-inverso isomers
NO322425B1 (no) * 2003-07-04 2006-10-02 Berge Biomed As Anvendelse av et hydrolysat av proteinholdig fiskemateriale for fremstilling av et farmasoytisk middel for behandling og/eller hindring av patologisk hoye nivaer av tracylglyceroler, hyperkolesterolemia, hyperhomocysteinemia, eller patologisk lave nivaer av beta-oksidasjon i et dyr eller menneske.
WO2006038327A1 (ja) * 2004-09-30 2006-04-13 Suntory Limited グロビン蛋白分解物を含有する酵母発酵飲料
CN101060854B (zh) * 2004-11-15 2012-02-08 爱沐健制药株式会社 具有抗糖尿病作用的蛋白质水解物
JP4395658B2 (ja) 2005-11-17 2010-01-13 エムジーファーマ株式会社 コレステロール再上昇抑制用組成物およびその用法
JP5175484B2 (ja) * 2007-03-30 2013-04-03 名古屋製酪株式会社 血中中性脂肪濃度上昇抑制剤
EP2179740B1 (en) * 2007-08-07 2014-10-08 Mg Pharma Inc. Anti-hypertensive agent
CN107556363B (zh) * 2016-06-30 2021-03-30 江西本草天工科技有限责任公司 肽或其盐及其制备方法
WO2018001273A1 (zh) * 2016-06-30 2018-01-04 江西本草天工科技有限责任公司 肽或其盐、其制备方法、及其制备预防和/或治疗肝损伤药物的用途
CN107551258B (zh) * 2016-06-30 2021-01-05 江西本草天工科技有限责任公司 用于预防和/或治疗肝损伤的vvyp
JP6832992B2 (ja) * 2018-09-12 2021-02-24 エムジーファーマ株式会社 抗肥満用組成物
JP2024102740A (ja) * 2023-01-19 2024-07-31 ロート製薬株式会社 疲労軽減又は疲労回復促進用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335567C (en) * 1988-02-02 1995-05-16 Kyoichi Kagawa Lipid metabolism promoting agent
US5723443A (en) * 1988-02-02 1998-03-03 Hankyu-Kyoei Bussan Co. Ltd. Lipid metabolism promoting agent and its use
JP2764276B2 (ja) * 1988-09-06 1998-06-11 仙味エキス株式会社 機能性新規ペプチド及びその利用
JPH0331298A (ja) * 1989-06-28 1991-02-12 Ajinomoto Co Inc プロリルエンドペプチターゼ阻害ペプチド
JPH03120224A (ja) * 1989-10-04 1991-05-22 Ajinomoto Co Inc 新規ペプチドおよびこれを含有する降圧剤
JP3312944B2 (ja) * 1993-03-24 2002-08-12 伊藤ハム株式会社 脂肪細胞分化抑制ペプチド及び当該ペプチドを有効成分とする脂肪細胞分化抑制剤
JP2800877B2 (ja) * 1993-12-28 1998-09-21 伊藤ハム株式会社 血中トリグリセリド濃度上昇抑制ペプチド及び当該ペプチドを有効成分として含む血中トリグリセリド濃度上昇抑制剤

Also Published As

Publication number Publication date
AU5912096A (en) 1997-10-17
NO325836B1 (no) 2008-07-28
AU690853B2 (en) 1998-04-30
WO1997035875A1 (en) 1997-10-02
EP0838473A4 (en) 2000-04-05
US5958885A (en) 1999-09-28
CA2221767C (en) 2001-01-23
NO975360D0 (no) 1997-11-21
EP0838473A1 (en) 1998-04-29
CA2221767A1 (en) 1997-10-02
EP0838473B1 (en) 2002-10-09
KR19990021880A (ko) 1999-03-25
KR100264344B1 (ko) 2000-08-16
JPH09255698A (ja) 1997-09-30
DK0838473T3 (da) 2003-02-17
NO975360L (no) 1998-01-21
ATE225803T1 (de) 2002-10-15
JP2805194B2 (ja) 1998-09-30

Similar Documents

Publication Publication Date Title
AU690853B2 (en) Peptide for inhibiting blood triglyceride level rise and inhibitor for blood triglyceride level rise comprising the peptide as active ingredient
Narici et al. Adaptability of elderly human muscles and tendons to increased loading
Sørensen et al. Effects of age and stocking density on leg weakness in broiler chickens
Su et al. A note on the effects of perches and litter substrate on leg weakness in broiler chickens
ES2153415T3 (es) Peptido inhibidor de la diferenciacion de adipocitos e inhibidor de la diferenciacion de adipocitos que contiene dicho peptido como ingrediente activo.
BRPI0413079A (pt) composição veterinária mastigável dútil saborosa
BR9408019A (pt) Composto composição util para aumentar a produção endógena ou a liberaçao de hormonio do crescimento em ser humano ou um animal e para o tratamento da osteoporose processos para aumentar os niveis de hormônio do crescimento em um ser humano ou um animal e a eficácia de alimentação promover o crescimento aumentar a produçao de leite e melhorar a qualidade da carcaça de gado para tratar ou previnir uma condição selecionada para tratar osteoporose e para preparar um composto
CA2433484A1 (en) Composition for use in animal nutrition comprising a controlled release lipid matrix, method for preparing the composition and method for the treatment of monogastric animals
PT1011723E (pt) Factor de crescimento tumorigenico de 88 kda e antagonistas
Croom et al. Neuropeptide Y, peptide YY and aluminum in Alzheimer’s disease:: Is there an etiological relationship?
Andrew et al. Nail bed ablation--excise or cauterise? A controlled study
Vaughan Flexural deformity of the carpus in puppies
Firth et al. Effects of racetrack exercise on third metacarpal and carpal bone of New Zealand thoroughbred horses
FI974601A0 (fi) Veren triglyseriditason kohoamista estävä peptidi ja mainittua peptidiä aktiivisena aineosana sisältävä veren triglyseriditason kohoamisen estäjä
Reiter et al. Effect of reduced weight load on locomotor activity and leg disorders in broiler chickens
DE69030732D1 (de) Antiparasitäre zusammensetzung zur verwendung bei tieren
Lloyd-Bauer et al. Correction of acquired flexural deformity by deep digital flexor tenotomy in a miniature horse
Shivaprakash et al. Incidence and management of congenital malformations of muscular system and limbs
Arnbjerg Changes in the distal phalanx in foals with deep digital flexor tendon contraction
RU2314111C1 (ru) Способ профилактики транспортного стресса крупного рогатого скота
RU2313940C1 (ru) Способ профилактики транспортного стресса свиней
Jansson et al. Acquired flexural deformity of the distalinterphalangeal joint in horses: Treatment by desmotomy of the accessory ligament of the deep digital flexor tendon: A retrospective study
Conklin Mechanical objectives: simplifying the approach to equine podiatry.
CA2225412A1 (en) A peptide inhibiting elevations of triglyceride levels in blood and an agent for inhibiting elevations of triglyceride levels in blood comprising the peptide as an active component
Carlton Beta-aminopropionitrile toxicity in the White Pekin duck